P

Pusan National University Hospital | Rheumatology

Research site
(Unclaimed)
Location
Seogu Gudeokro 179, Busan, North Gyeongsang, South Korea
Site insights

Top conditions

Lymphoma (11 trials)

B-Cell Lymphoma (7 trials)

Diffuse Large B-Cell Lymphoma (6 trials)

Edema (5 trials)

Macular Edema (5 trials)

Top treatments

Lenalidomide
Polatuzumab
Cyclophosphamide
Vamikibart
Doxorubicin
Prednisone
Ranibizumab
Talazoparib
Mosunetuzumab
RO7200220

Parent organization

This site is a part of Pusan National University Hospital

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

42 of 51
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A C5 Inhibitor-controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy (ACCESS-1)

The study is researching a clinical treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on patien...

Enrolling
Paroxysmal Nocturnal Hemoglobinuria
Drug: Eculizumab
Drug: Pozelimab
Locations recently updated

This study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic o...

Active, not recruiting
Chronic Migraine
Episodic Migraine
Drug: Atogepant 60 mg

This study (study ID PAC203 North America; PAC303 ex-North America) is evaluating 200 mg BID of pacritinib compared to physician's choice (P/C) thera...

Enrolling
Post-essential Thrombocythemia Myelofibrosis
Post-polycythemia Vera Myelofibrosis
Drug: Physician's Choice medications
Drug: Pacritinib

The drug that will be investigated in the study is an antibody, epcoritamab, also known as EPKINLY™ and GEN3013. Since the safety and tolerability of...

Active, not recruiting
Diffuse Large B-cell Lymphoma
Drug: Investigator's Choice Chemotherapy
Biological: Epcoritamab

This study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituxima...

Enrolling
Diffuse Large B-cell Lymphoma
Drug: Oxaliplatin
Drug: Rituxumab

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plu...

Active, not recruiting
Diffuse Large B-Cell Lymphoma
Drug: Polatuzumab vedotin Placebo
Drug: Vincristine Placebo

This study will evaluate the efficacy, safety, and pharmacokinetics of inavolisib in combination with palbociclib and fulvestrant compared with place...

Active, not recruiting
Breast Cancer
Drug: Placebo
Drug: Palbociclib

This study will evaluate the efficacy and safety of mosunetuzumab in combination with lenalidomide (M + Len) compared to rituximab in combination wit...

Enrolling
Relapsed or Refractory Follicular Lymphoma
Drug: Lenalidomide
Drug: Rituximab
Locations recently updated

The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of divarasib combined with other anti-cancer therapies in pa...

Enrolling
Non-Small Cell Lung Cancer
Drug: Pemetrexed
Drug: Divarasib

The reason for this study is to assess the safety and efficacy of donanemab in participants with early Alzheimer's disease. The study duration includ...

Enrolling
Alzheimer Disease
Mental Disorders
Drug: Placebo
Drug: Donanemab

This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGV...

Enrolling
aGVHD
Graft Versus Host Disease
Biological: Itolizumab
Drug: EQ001 Placebo

The purpose of this study is to evaluate the safety, tolerability, and efficacy of mavacamten compared with placebo in participants with symptomatic...

Enrolling
Cardiomyopathy, Hypertrophic
Drug: Mavacamten
Other: Placebo

Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokin...

Enrolling
Neovascular Age-related Macular Degeneration (nAMD)
Device: Port Delivery System with Ranibizumab
Drug: Ranibizumab

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of tobemstomig (RO7247669) in combination with platinum-based che...

Active, not recruiting
Non-small Cell Lung Cancer
Drug: Paclitaxel
Drug: Pemetrexed

This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study...

Enrolling
Diffuse Large B-cell Lymphoma (DLBCL)
Drug: Doxorubicin
Drug: Prednisone/Prednisolone

The purpose of this study is to compare the effectiveness of iberdomide maintenance to lenalidomide maintenance therapy after autologous stem cell tr...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Iberdomide

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Active, not recruiting
Atopic Dermatitis
Drug: Upadacitinib
Drug: Dupilumab
Locations recently updated

The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide,...

Enrolling
Relapsed or Refractory Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

A Phase 3 study to evaluate the efficacy and safety of birtamimab plus standard of care compared to placebo plus standard of care in Mayo Stage IV pa...

Enrolling
Light Chain (AL) Amyloidosis
Other: Placebo
Drug: Standard of Care Chemotherapy

Trial sponsors

Roche logo

Roche (14 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems